Vera Therapeutics Q1 net loss $28.4M; cash $403.7M; Phase 3 enrollment on track

Vera Therapeutics, Inc.

2024-Q1 EPS reported -$0.56

Net loss of $28.4M ($0.56 diluted EPS) vs $30.1M ($0.80) in Q1 2023.
Cash and equivalents $403.7M after $287.5M financing; runway through approval and launch.
Positive 72-week Phase 2b ORIGIN data; 96-week topline results expected Q4 2024.
Pivotal Phase 3 ORIGIN 3 enrollment estimated complete Q3 2024; data 1H 2025.
Appointed Robert M. Brenner as CMO and William D. Turner as CDO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vera Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $28.4 million, or a net loss per diluted share of $0.56, EPS net loss per diluted share of $0.56.

Period: the first quarter ended March 31, 2024
Net income: net loss of $28.4 million, or a net loss per diluted share of $0.56
EPS: net loss per diluted share of $0.56
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2024, the company reported a net loss of $28.4 million, or a net loss per diluted share of $0.56, compared to a net loss of $30.1 million, or a net loss per diluted share of $0.80, for the same period last year.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056283

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.